These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19958861)

  • 1. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).
    Margolis KL; Dunn K; Simpson LM; Ford CE; Williamson JD; Gordon DJ; Einhorn PT; Probstfield JL;
    Am Heart J; 2009 Dec; 158(6):948-55. PubMed ID: 19958861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    Margolis KL; Davis BR; Baimbridge C; Ciocon JO; Cuyjet AB; Dart RA; Einhorn PT; Ford CE; Gordon D; Hartney TJ; Julian Haywood L; Holtzman J; Mathis DE; Oparil S; Probstfield JL; Simpson LM; Stokes JD; Wiegmann TB; Williamson JD;
    J Clin Hypertens (Greenwich); 2013 Aug; 15(8):542-54. PubMed ID: 23889716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
    Rahman M; Baimbridge C; Davis BR; Barzilay JI; Basile JN; Henriquez MA; Huml A; Kopyt N; Louis GT; Pressel SL; Rosendorff C; Sastrasinh S; Stanford C;
    Clin Nephrol; 2013 Oct; 80(4):235-48. PubMed ID: 23816477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of the month. The ALLHAT-LLT trial].
    Kulbertus H; Scheen AJ
    Rev Med Liege; 2003 Jan; 58(1):53-8. PubMed ID: 12647600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
    Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
    JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
    Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Baimbridge C; Davis BR; Barzilay J; Basile JN; Henriquez MA; Huml A; Kopyt N; Louis GT; Pressel SL; Rosendorff C; Sastrasinh S; Stanford C;
    Am J Kidney Dis; 2008 Sep; 52(3):412-24. PubMed ID: 18676075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
    J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Maitland-van der Zee AH; Boerwinkle E; Arnett DK; Davis BR; Leiendecker-Foster C; Miller MB; Klungel OH; Ford CE; Eckfeldt JH
    Am Heart J; 2007 Jan; 153(1):54-8. PubMed ID: 17174637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALLHAT-LLT: questions, questions, and more questions (and some answers).
    Skerrett PJ; Pasternak RC
    Curr Atheroscler Rep; 2004 Sep; 6(5):375-80. PubMed ID: 15296704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.
    Maitland-van der Zee AH; Peters BJ; Lynch AI; Boerwinkle E; Arnett DK; Cheng S; Davis BR; Leiendecker-Foster C; Ford CE; Eckfeldt JH
    Pharmacogenet Genomics; 2009 May; 19(5):338-44. PubMed ID: 19415820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD;
    Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
    Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
    J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.